Trial Profile

Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plerixafor (Primary)
Indications Sickle cell anaemia
Focus Therapeutic Use

Most Recent Events

14 Dec 2021 Results reporting optimization of autologous hematopoietic progenitor stem cell apheresis collection from Plerixafor mobilized patients enrolled on two clinical trials (NCT03226691 and NCT04443907) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
06 Nov 2019 Results assessing efficacy and safety of plerixafor mobilization in patients with sickle cell disease, released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
28 Feb 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com